The First in China! BLA Submitted for Luzhu Biotech’s Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026
Hongkong – February 11, 2025 – (SeaPRwire) – On Feb. 9, 2025, the official website of the Center for Drug Evaluation, National Medical Products Administration of China indicates that the Biologics License Application (BLA) for Luzhu Biotech’s (2480.HK) biological product for prophylaxis, Recombinant Herpes Zoster Vaccine (CHO Cells), has been accepted. This vaccine is the second recombinant herpes zoster vaccine worldwide—following GSK’s Shingrix—and the first of its kind to be submitted for market approval in China.
Translated version
Origin version
01
How Big Is the Herpes Zoster Vaccine Market?
BCHT’s Ganwei is currently the only domestically marketed herpes zoster vaccine in China. Since its launch in 2023, it has generated nearly RMB900 million in sales within the year, drawing significant market attention and rapidly intensifying competition in the field. As of Dec. 31, 2024, over 20 companies in China have advanced their herpes zoster vaccine pipelines into clinical trials or received In…